Liquid Biopsies Are Important in Lung Cancer, Expert Says

Liquid biopsies are quick, convenient and a crucial part of planning treatment for many patients with lung cancer, says Luis E. Raez, M.D.
BY GINA COLUMBUS @ginacolumbusonc
PUBLISHED: DECEMBER 31, 2016
Liquid biopsies, such as plasma- and urine-based assays, are able to detect mutations in patients with non-small cell lung cancer (NSCLC), playing a crucial role in treatment planning for these patients, says Luis E. Raez, M.D.

The liquid biopsies, he says, provide a more convenient and quicker alternative to the standard tissue biopsy. And, if a target is detected, physicians can line up a number of available therapies to begin treatment.

The emergence of liquid biopsies is not the only notable advance in NSCLC, says Ruiz. The explosion of targeted agents and immunotherapies has drastically enhanced treatment options in the field, and researchers are actively working on identifying more targets to hopefully one day be able to eliminate chemotherapy.

In an interview, Raez, medical director of Memorial Cancer Institute, Memorial Healthcare System discussed the significance of liquid biopsies in lung cancer, as well as other breakthroughs and remaining challenges in the field.

Please discuss the emergence of liquid biopsies in lung cancer.

Nowadays, the therapy for lung cancer is based on targets. We have been very lucky in that we don’t give chemotherapy widespread anymore. Now, we target the tumor. The main goal now is to identify a target for a patient’s lung cancer tumor.

In that regard, it is very important to do biopsies. However, the biopsies are not easy, because every time you put in a needle, you cause pneumothorax and discomfort.

That’s why I spoke today about liquid biopsies. We start from the blood or urine, and we can get the same information that we get from the tissue. That is the advantage of the liquid biopsies technology as an alternative to the conservative tissue biopsy. It’s less costly, less painful, and is better for the quality of life of the patients and gives us a lot of information.

There are times when it doesn't seem that there is enough tissue available.

Yes, that is a very important point. The first biopsy is always the standard because you don’t know what tumor a patient has; you have to put a needle in to see. A lot of times, there is not enough tissue. That is why the liquid biopsies are an alternative; there are numerous times that you can draw blood and give urine samples. That is the benefit of the liquid biopsies compared with tissue.

The other benefit is that the liquid biopsies can be done serially. The only way that I would know that a patient is doing better or worse is by looking at their pictures—measuring the pictures of the patient with CT or PET scans. We try to predict if the patient is getting better or worse based on shrinking or increasing changes in size. Now, liquid biopsies give the possibility to measure how much tumor a patient carries in their blood. If we are successful, we are getting rid of the tumor; if we’re not successful, then there is more of the tumor in their blood. That’s probably more accurate than taking pictures.

For the benefit of the patient, it is also less radiation exposure. When you think of having these CT scans or PET scans, it is associated with a lot of radiation. Liquid biopsies bring the opportunity to do a more sophisticated, scientific tracking of the tumors with less harm for the patients.

Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Do Genes and Gender Play a Role in Chemotherapy-Related Fatigue?
Genetics may play a role in chemotherapy-related fatigue, according to a recent study.
Excitement Grows for Immunotherapy in Lung Cancer
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
Personalized Treatment Needed for Advanced Lung Cancer
A more personalized approach is needed in treatment plans for patients with stage 3 non-small cell lung cancer (NSCLC), according to Thomas A. Hensing, M.D.
Related Videos
Examining the Role of Stress in Lung Cancer
Syed Jafri, M.D., an assistant professor at the University of Texas McGovern School of Medicine, discusses the potential role that stress could play in lung cancer diagnoses.
Chris Draft on What Caregivers Should Know
NFL player and founder of the Chris Draft Family Foundation, Chris Draft, explains what caregivers need to know. 
What's Next in Immunotherapy?
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
x
//For side ad protocol